MedPath

Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Clinical Trials
Related News

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Phase 2
Completed
Conditions
Neoplasms, Ovarian
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Interventions
First Posted Date
2006-01-25
Last Posted Date
2018-09-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
35
Registration Number
NCT00281632
Locations
🇸🇬

GSK Investigational Site, Singapore, Singapore

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
First Posted Date
2005-11-22
Last Posted Date
2017-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
100
Registration Number
NCT00256880
Locations
🇦🇺

GSK Investigational Site, Melbourne, Victoria, Australia

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Placebo
First Posted Date
2005-10-27
Last Posted Date
2017-03-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
225
Registration Number
NCT00244764
Locations
🇨🇳

GSK Investigational Site, Taipei, Taiwan

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Phase 1
Completed
Conditions
Carcinoma, Renal Cell
Interventions
First Posted Date
2005-09-12
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
75
Registration Number
NCT00158782
Locations
🇳🇱

GSK Investigational Site, Rotterdam, Netherlands

GW786034 in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2003-05-07
Last Posted Date
2013-09-20
Lead Sponsor
Case Comprehensive Cancer Center
Registration Number
NCT00060151
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

🇺🇸

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy